Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27048068 | 0.86 | ATP1A1 (0.40) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL25839392 | 0.83 | LGALS3 (0.40) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL26829174 | 0.81 | LGALS8 (0.39) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL25949411 | 0.79 | LGALS8 (0.39) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL24491012 | 0.77 | LGALS3 (0.41) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL10083815 | 0.77 | LGALS3 (0.47) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL12320208 | 0.77 | LGALS3 (0.47) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL24473712 | 0.77 | LGALS3 (0.41) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL10082991 | 0.77 | LGALS3 (0.47) | LGALS3LGALS8LGALS4PTPN1GAA | |
| SCHEMBL15739307 | 0.77 | LGALS3 (0.47) | LGALS3LGALS8LGALS4PTPN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140295566-A1 | CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140295566-A1 | CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140295566-A1 | CARBOHYDRATE-LIGAND CONJUGATES AND THEIR APPLICATION FOR THE ANALYSIS OF CARBOHYDRATE-PROTEIN INTERACTION | CA11, CA14, OSTC | LGALS3 163/4885LGALS8 175/4885LGALS4 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.